FMP
XOMA Corporation
XOMA
NASDAQ
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
19.24 USD
-0.2 (-1.04%)
Latest XOMA News
Zacks Investment Research
Aug 13, 2024
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
XOMA Royalty (XOMA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.59 per share a year ago.
Seeking Alpha
Jul 19, 2024
My 2 Top Royalty Income Picks, Yields Up To 9.5%
My 2 Top Royalty Income Picks, Yields Up To 9.5%
Zacks Investment Research
Jul 18, 2024
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Seeking Alpha
Jun 29, 2024
XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA's diverse IP portfolio spans various therapeutic areas, including oncology, immunology, rare diseases, and acute pain, mitigating investment risks. The recent acquisition of Kinnate Biopharma extends XOMA's portfolio into oncology despite Kinnate selling its crown jewel, exarafenib, before the acquisition.
Zacks Investment Research
Jun 21, 2024
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
InvestorPlace
Jun 12, 2024
3 Crazy Good Stocks to Buy With $500 Right Now
Although there was a time when the stock market was solely the playground of the wealthy, it no longer takes money to make money on Wall Street. The democratization of investing means even those with only a few dollars to spare can start building a retirement nest egg — and it won't even cost you anything to buy and sell shares.
GlobeNewsWire
May 14, 2024
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.
Zacks Investment Research
May 7, 2024
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewsWire
Feb 28, 2024
XOMA to Present at Upcoming Investor Conferences in March
EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences:
Seeking Alpha
Dec 15, 2023
I'm Buying Preferred Stocks Hand Over Fist
Preferred shares present a desirable trifecta of high yields, lower risk, and significant capital upside. At these bargain prices, preferred stocks have something for value, income, and growth investors. We discuss two +9% yielding preferreds for your passive income needs.
